
Affimed N.V. AFMD
Quartalsbericht 2022-Q2
hinzugefügt 11.08.2022
Affimed N.V. Gesamtes Eigenkapital 2011-2026 | AFMD
Gesamtes Eigenkapital Jährlich Affimed N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 72 M | 38.7 M | 40.1 M | 38.9 M | 38.8 M | 67.3 M | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 72 M | 38.7 M | 49.3 M |
Gesamtes Eigenkapital Vierteljährlich Affimed N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 193 M | - | 136 M | - | 151 M | - | 72 M | - | 40.5 M | - | 38.7 M | - | 32.8 M | - | 40.1 M | - | 47.2 M | - | 38.9 M | - | - | - | 38.8 M | - | - | - | 67.3 M | - | - | - | 31.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 193 M | 31.8 M | 71.4 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
53.5 M | $ 8.53 | -2.18 % | $ 84.3 M | ||
|
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | ||
|
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.73 | 1.78 % | $ 8.97 B | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | ||
|
BioNTech SE
BNTX
|
1.37 B | $ 98.87 | 2.24 % | $ 27.2 B | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | ||
|
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Burford Capital Limited
BUR
|
1.7 B | $ 4.68 | 4.23 % | $ 760 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | ||
|
Cabaletta Bio
CABA
|
112 M | $ 3.26 | 1.72 % | $ 328 M | ||
|
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | ||
|
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
195 M | - | - | $ 546 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 21.44 | 0.37 % | $ 1 B | ||
|
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
-15.9 M | - | - | $ 25.3 M | ||
|
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
32.6 M | $ 1.53 | 4.08 % | $ 393 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.01 | 3.08 % | $ 4.96 M | ||
|
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.14 | -1.31 % | $ 443 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 25.31 | 4.93 % | $ 3.22 B | ||
|
Chimerix
CMRX
|
193 M | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
527 M | $ 33.28 | 2.1 % | $ 2.21 B | ||
|
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.49 | 1.02 % | $ 397 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
163 M | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | ||
|
CNS Pharmaceuticals
CNSP
|
4.52 M | $ 2.51 | 3.08 % | $ 1.11 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
15.6 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
CTI BioPharma Corp.
CTIC
|
-17.6 M | - | - | $ 1.2 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Akari Therapeutics, Plc
AKTX
|
28.3 M | $ 4.57 | 9.07 % | $ 308 B |